TKI for Advanced HCC: Second Line
TKIs for Advanced HCC in the Second Line and Beyond

Released: February 22, 2022

Expiration: February 21, 2023

Activity

Progress
1
Course Completed

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss second line treatment of patients with advanced hepatocellular carcinoma. Topics include:

  • Available agents for the management of advanced hepatocellular carcinoma in the second line
  • The current role of tyrosine kinase inhibitors in second-line treatment of advanced hepatocellular carcinoma
  • Ongoing clinical trials in the second-line setting